Transcript 0:00 [upbeat music] Andrew, so great to have you on the podcast. How are you today? Hey, Jared. Doing well. Um, thank you for having me. It's wonderful to be here. Good to see you again. Absolutely. 0:13 It's been a l- little bit of time since, I know we did a clip a while back, but first time having you on the podcast. 0:19 I always love whenever we have a guest on for the first time, so would love if you could just tell us a little bit about yourself, and then we'll talk about, you know, what you've been building, give us an update, and we'll go from there. 0:29 Yeah. My name is Andrew Kobylinski, CEO and co-founder of Primary.Health. My background is in digital health. 0:35 I was a, an engineer at Healthline Networks, helping build that media property, which, um, really taught me a lot about digital health and semantic search engines, ontologies, terminologies, SNOMED, interoperability, provider data challenges. 0:50 Uh, a career there serving many roles from being a developer to a product manager to business development and sales. Even when I left there, I was still coding a little bit. 1:00 Um, really set me up to understand that healthcare has a lot of foundational basic problems, and so I've always been tackling those kinds of issues. 1:10 Early in the pandemic, I found myself without a job after, um, help- successfully helping Better Doctor find a new home with Quest Analytics in the network adequacy space. 1:22 And I volunteered for an effort of UCSF doctors trying to enable community-based testing and COVID response. So I took over full-time leadership of a few volunteer engineers, and we started coding all night. 1:34 I would put my baby daughter down to bed at eight o'clock, and we'd do a standup at 8:30, um, and code until 2:00 in the morning. 1:41 And so I'm very much an accidental founder of Primary Health, um, a COVID-born public health software infrastructure company. 1:49 Um, yeah, it's been a wild ride and, but still rooted in our basics of coding really good digital health solutions. What do you wish more people knew about Primary.Health that maybe they don't know? 2:00 Um, we tend to work on the unsexy problems that are somewhat simple. So for example, in public health, a lot of public health work happens on paper forms. 2:13 And you ask why in 2025 are, you know, we have interoperability, we have digital ordering, we have OCR technology, why, why are people manually entering paper forms? 2:25 And I would kind of look at it and s- look at that problem and say, number one, there hasn't been any VC-funded companies building a software stack for public health, so there hasn't been any innovation in this space coming in from other domains or founders from other verticals bringing technology in. 2:43 It's largely a, a community that's self trying to improve, meaning state departments of health and their IT teams trying to fix things themselves. 2:52 And then more fundamentally, public health suffers from a lot of the grant l- language barriers. So when CDC says to do something a certain way in a funding bucket, that can be very, very restrictive. 3:05 So simple things like an OCR technology that a startup like Primary Health can optimize. Now with these AI engines, the accuracy is better than humans. We could deploy that throughout public health in a month and a half. 3:17 We've done projects like that during the pandemic. Actually doing that today in the current climate of public health is very slow and difficult. But I guess that's the secret. 3:30 Like, it's an untapped market of very simple problems and workflow issues that need to be solved, and we're one of the very few companies actually addressing the space. 3:39 I love that you've decided to focus on, on public health, and talk, talk me through a little bit why it seems like, you know, there's, there's lots of areas of healthcare. 3:48 We always hear about innovation happening or all these different companies launching. We don't hear that as much in the public health space. So talk me through why y- you think that is and, and maybe how do we... 4:00 I know you've decided to, to change that and, and, and do your part, but why, why is that the case, and then how do we maybe get past that? It's a good question. 4:10 I, I think there are two foundational problems that have held back the space. Number one, investors don't understand the space. 4:18 Very few in- investors even understand digital health, let alone a subset of it, of healthcare, public health, and operations. It's a complex space, highly regulated. 4:28 Your purchaser is largely government, um, but it's also hybrid, so it has to deal with insurance re- reimbursement. Nothing is in this space is very difficult. 4:38 It's just that there's a million little things that have to come together, like a very complex 1,000, 2,000-piece puzzle to make a public health program work. So I think that's the fundamental issue. 4:52 You don't have investors who understand that complexity. And then second, just the thesis, the hybrid thesis that true public health is public-private kind of partnership. 5:04 So in our world, where we work with vaccine makers and public health department and states, we help facilitate this hybrid relationship where each entity is paying us to perform a portion of the solution. 5:17 Um, and that together creates a comprehensive solution. 5:21 But a small startup pitching to a VC, "We're gonna go after pharma companies and government sector," most VCs will just laugh you out of the room, but that's fundamentally how you have to approach the market. 5:32 Now, there's obviously, there's some great VCs out there, like we're, uh, I just wanna bring this up because I, I do hear this, though, a lot from, from more so on the digital, just straight-up digital health side of things, right? 5:43 That there are a, a vast majority of the investors that don't maybe fully understand the space. But that's all I hear. How would you suggest they maybe get a little bit more up to speed? 5:54 Do they need a solid clinical advisory team? Like, what, what is your advice to the VCs that maybe realize they don't know as much about these particular areas but want to, truly? 6:06 Take some risks, jump in with a few startups in the space and learn. I like it. The, the best things are obvious, right? Yeah, do your job. Yep. Take some risk. Yeah. I like it. Exactly. 6:16 Yeah, at the end of the day, I think the VCs, VCs will start to recognize a new thesis emerging in this space, which is that as traditional public health, as Medicaid are weakened, the needs in the population go up, and the population seeks retail options in that scenario. 6:33 If you can't get a vaccine from your local public health department, can you get it at CVS? Can you get a good discount on it? Will GoodRx do a discount card for that? All these things start to become much more relevant. 6:45 So I see the... 6:47 In the current state of what's happening in the market, as public health is weakened and we see the reemergence of diseases that shouldn't be here anymore, like measles and soon other things, the public will be seeking retail options because you'll have a gr- larger and larger percentage of the population uninsured, have to pay out-of-pocket, costs are going up. 7:06 So investors should definitely look at the space from that perspective. Those who can bridge the public-private retail health with public health services. The needs, the consumer needs are just off the chart. Now, 7:18 there, there was multiple reasons I was excited to have you on the podcast here today, one of which was to talk a little bit about just vaccine policy changing. You know this, right? Providers are running away. 7:31 Would love to hear your thoughts on where things are heading and just, I guess, you know, are, are there any call to actions for vaccine makers to, to help, you know, modernize public health infrastructure? Yes. 7:43 First off, I'll say to all public health nurses and staff who work in the world of immunizations, thank you for everything you do. This is definitely a challenging period to navigate. 7:53 Things that seem minor, for example, the recent ACIP meeting recommendations not to vote against any, you know, um, multi-dose vials that had thimerosal in it. 8:04 Multi-dose vials are actually quite important for public health programs. Programs that have very little budgets are trying to maximize every single dose to reduce the cost to make it available to more people. 8:17 So make every dollar stretch that much further, five, 10% is super important. So a multi-dose vial at a, you know, flu shot clinic where you can do two times the vaccine work for half the cost, so half the waste, um, 8:31 that's a key tool in running programs. 8:34 So what we're seeing is these changes are slowly kind of whittling away and eliminating some of the tools that public health have for running efficient programs while also reducing their top-line budgets. 8:45 So public health overall in the vaccine business is shifting. 8:51 What that means is, as public health is weakened, additionally, these changes also make the unit economics worse for providers, so less providers want to be in the vaccine business. 9:01 That means providers are willing to refer the patients somewhere else to get their shots. 9:05 So we're gonna see this continued trend towards retail health for vaccine work, where a pharmacy, for example, has better unit economics to run a vaccine program. 9:14 In addition, you're gonna see a lot of simplification of vaccine work. So a competitor of ours, VaxCare, um, has emerged kind of in the vaccine RCM revenue cycle and management kind of business. 9:28 And so creating new billing solutions that take away some of the administrative work of vaccines and inventory management is a huge benefit to providers and pharmacies, et cetera, because it means that on a business that has very little margin, you can kind of recoup a little bit more margin. 9:44 So I think the shift in the vaccine business is kind of threefold. I'll start with the public health side, which is the education side. CDC is not doing a lot of education these days. 9:54 So it's now up to local health departments and health plans to lead, and providers to lead education campaigns around, "You need this vaccine. You need the HPV vaccine," et cetera. 10:06 These are amazing tools to reduce disease rates, reduce cancers. That saves healthcare system costs. So those who have the incentive need to take up the education mantle and roll that out. 10:17 Second, providers, there's a lot of confusion. So I look at the vaccine hesitancy problem from multiple lenses. One, there's, yes, just the deliberate misinformation by certain individuals. That's a contributing factor. 10:31 But also, some of the successes during the pandemic have actually caused a lot of confusion. A whole new vaccine platform, mRNA, new technologies, new vaccines, differentiation between vaccine brands. 10:44 It used to be that a provider said, "You just need this vaccine," and you get that shot. Now, a consumer actually has a choice. Which of these RSV vaccines is better for me? I want this brand or this brand. 10:54 Like, there's variation in the market. So some of the success is also creating complexity, which creates confusion, which also confusion leads to delay, and that is also very much part of that hesitancy bucket. 11:07 So providers at the end of the day, and consumers need a new set of tools to help 11:11 you understand what vaccines you actually need, when you need them, why you need them, and which product to get and where to get that product. 11:19 It becomes a very complex matrix of variables that the current system is not built to support. Super interesting. I mentioned that was one of the reasons I wanted to have you on. 11:27 Another reason was, you know, in, in conversation, you and I chatted a little bit, and I don't know how I missed this originally, but it's been pretty incredible what you've been able to accomplish, especially when people find out that you did not raise VC funding. 11:43 So would love to hear, uh, you know, if there's any numbers, if there's any, you know, points towards, like, anything that you wanna share regarding that. 11:50 But then also, I know our audience would also love to hear any tips and suggestions you have. I think, you know, years ago, that was always the path that people pursued always, right? 12:02 And now, with how much AI has progressed and some other factors, some people are starting to talk more about bootstrapping. 12:08 And, and if they're not bootstrapping entirely, like just angel funding and then going from there. 12:12 Would love to hear w- how you've been able to do this, any metrics that you wanna share, and then any tips you have for that next wave of entrepreneurs that wanna do something similar, raising no VC funding. 12:23 Yeah, absolutely. So it's been an interesting path. 12:27 [laughs] I view myself like accidental CEO, accidental founder 'cause I joined a volunteer effort, and we've made a company out of it, so there was no investor deck or thesis at the beginning. 12:37 The pandemic broke a lot of catch-22s. 12:40 So to give you some perspective of the scale, since founding in twenty twenty, the company's done over a hundred and twenty million in revenue, all s-software licensing and supporting services around that revenue. 12:53 We were at our peak around two hundred people, and today we operate break even with cash reserves and kind of self-funding the next chapter of the company post-pandemic. A lot of lessons through that experience. 13:05 I'm not a repeat CEO, so it's my first time as well, so a lot of mistakes made during that period. 13:11 We would absolutely have taken VC funding earlier on, uh, but simply put, the, the folks we spoke to didn't understand the public health market and what we were doing, and so it was just very difficult to raise, and we didn't have time to raise. 13:25 We would go from a call with the governor trying to get a new testing program off the ground and, you know, all-night coding sessions to get vaccine systems up for an early vaccine launch. 13:36 We just never really had time to do the traditional roadshow. Um, Jared, like probably most of the CEOs you speak with, their full-time job is fundraising. They're probably doing thirty hours a week of fundraising. 13:47 Myself, maybe had two hours a week to speak with investors. Just wouldn't have the time in the pandemic. 13:53 So we got lucky in that a lot of public health departments took a risk with us, and we were able to do client-funded growth. I really do believe in that. 14:01 If you can use client-funded growth to kind of skip a funding round or two, that, that is great. But there's a lot of merit in VC funding as well. 14:09 When you're tackling a problem such as looking at RCM space where there's a lot of competitors, and RCM for public health is still a huge problem. No one's really solved it. 14:19 You're seeing some competitors make inroads, and it's very, you know... it's a good business. 14:24 But where you have entrenched competitors, VC funding can help you do a more aggressive strategy and a market share strategy that you just can't do with self-funding. You're too conservative inherently. 14:34 But a lot of lessons, good, bad. At the end of the day, I think for a company focused on public health, we're able to stay truer to our mission without a board that's guiding us to an exit thesis. 14:46 Yeah, and, and by the way, like you and I are both... we're not knocking VC funding at all. 14:51 It has its, it has its place, and there's certainly businesses that-- I think there's a lot of businesses that may have been around today if they were able to have gotten the funding, and I think there's a lot of businesses that, um, 15:02 you know, maybe, maybe didn't need to and then t- Hey, that's, that's a lesson that they ended up learning. What's next for, for Primary.Health as we wrap up here? We are pushing forward. 15:09 We're trying to create additional client relationships on the public-private, um, kind of public health problem. Vaccine makers, work with us. We work with some of you. [laughs] All of you work with us. 15:20 Public health departments, I would love to work with you more on modernizing the stack. 15:25 Many of you made investments in Salesforce and Microsoft and that kind of infrastructure during the pandemic, and many of you are shutting down that infrastructure rather than, um, looking at vendors like us that are cra- It's crazy to say this, but we're five percent the cost of those solutions with more functionality. 15:45 Um, and so it's been, I think, cognitively difficult for a lot of public health IT leaders to understand that the pandemic scale funding doesn't mean you can't have tech solutions in non-pandemic scale world. 16:00 So going forward, I would really challenge public health leaders and our private sector partners, if we want really good public health in this country, we need to come together and collaborate, shared platforms that really get these public health workflows back at scale. 16:15 One example is we're in a, we're in about twenty community-based churches, and in those settings, forty percent of these congregations haven't been to a PCP in ten years. 16:27 This is a massive population that hasn't had basic immunizations, testing, screening work, et cetera. 16:33 So if we wanna solve these problems of bringing healthcare and preventative services to these populations, we need to collaborate much more strongly public-private, and that requires a mental shift on public health part and the private sector's part and role. 16:46 I'm seeing that start to happen, so I'm optimistic. Uh, we'll see how this fall's immunization campaigns go. Andrew, it's been a real pleasure. 16:54 Look forward to future chats, and, uh, hope to run into you at some of these events coming up over the next few months. Absolutely, Jared. Thank you so much. [outro jingle]